文献速递胰腺与胆道疾病消化道肿瘤与早癌

胰腺分支胰管型IPMN进展风险分层工具开发

Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression.
PubMed 文献 · Aliment Pharmacol Ther · 2019-08-19

研究基于三家学术机构前瞻性胰腺囊肿监测数据库,纳入875例基线无担忧特征或高危征象的假定分支胰管型IPMN患者,随访≥12个月,构建Cox比例风险预测模型并内部-外部验证。平均随访50个月,116例(13%)出现担忧特征或高危征象;最终模型含囊肿大小、多灶性、吸烟史、急性胰腺炎史和胰腺外恶性肿瘤史,各队列C统计量为0.72、0.71和0.64。

要点

  • DART-1模型可识别进展风险最低的假定分支胰管型IPMN。
  • 模型纳入囊肿大小、多灶性、吸烟、急性胰腺炎史和胰腺外恶性肿瘤史。
  • 验证队列C统计量为0.72、0.71和0.64。

核心结论

  • 在基线无担忧特征或高危征象的假定分支胰管型IPMN中,DART-1成功识别进展为担忧特征或高危征象低风险的胰腺病变。

研究设计与样本

  • 研究结合三家学术机构前瞻性维护的胰腺囊肿监测数据库,纳入基线无担忧特征或高危征象(按2012年国际Fukuoka指南定义)且随访≥12个月的假定分支胰管型IPMN患者,共875例。
  • 研究使用Cox比例风险回归分析构建多变量预测模型,并进行内部-外部验证。

主要发现

  • 平均随访50个月(范围12-157个月),116例(13%)患者出现担忧特征或高危征象。
  • 最终模型包含囊肿大小(HR 1.12,95%CI 1.09-1.15)、囊肿多灶性(HR 1.49,95%CI 1.01-2.18)、曾经吸烟(HR 1.40,95%CI 0.95-2.04)、急性胰腺炎史(HR 2.07,95%CI 1.21-3.55)和胰腺外恶性肿瘤史(HR 1.34,95%CI 0.91-1.97)。
  • 验证后模型区分能力良好:Mayo队列C统计量0.72,Columbia队列0.71,Erasmus队列0.64。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Because most pancreatic intraductal papillary mucinous neoplasms (IPMNs) will never become malignant, currently advocated long-term surveillance is low-yield for most individuals. AIM: To develop a score chart identifying IPMNs at lowest risk of developing worrisome features or high-risk stigmata. METHODS: We combined prospectively maintained pancreatic cyst surveillance databases of three academic institutions. Patients were included if they had a presumed side-branch IPMN, without worrisome features or high-risk stigmata at baseline (as defined by the 2012 international Fukuoka guidelines), and were followed ≥ 12 months. The endpoint was development of one or more worrisome features or high-risk stigmata during follow-up. We created a multivariable prediction model using Cox-proportional logistic regression analysis and performed an internal-external validation. RESULTS: 875 patients were included. After a mean follow-up of 50 months (range 12-157), 116 (13%) patients developed worrisome features or high-risk stigmata. The final model included cyst size (HR 1.12, 95% CI 1.09-1.15), cyst multifocality (HR 1.49, 95% CI 1.01-2.18), ever having smoked (HR 1.40, 95% CI 0.95-2.04), history of acute pancreatitis (HR 2.07, 95% CI 1.21-3.55), and history of extrapancreatic malignancy (HR 1.34, 95% CI 0.91-1.97). After validation, the model had good discriminative ability (C-statistic 0.72 in the Mayo cohort, 0.71 in the Columbia cohort, 0.64 in the Erasmus cohort). CONCLUSION: In presumed side branch IPMNs without worrisome features or high-risk stigmata at baseline, the Dutch-American Risk stratification Tool (DART-1) successfully identifies pancreatic lesions at low risk of developing worrisome features or high-risk stigmata.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Overbeek KA, Alblas M, Gausman V, et al. Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression. Aliment Pharmacol Ther. 2019. PMID: 31429105. doi:10.1111/apt.15440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。